These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21554028)

  • 1. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
    Sher A; Wu S
    Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
    Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
    Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
    Schutz FA; Jardim DL; Je Y; Choueiri TK
    Eur J Cancer; 2011 May; 47(8):1161-74. PubMed ID: 21470847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
    Shameem R; Hamid MS; Wu S
    Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
    Ranpura V; Hapani S; Chuang J; Wu S
    Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
    Choueiri TK; Mayer EL; Je Y; Rosenberg JE; Nguyen PL; Azzi GR; Bellmunt J; Burstein HJ; Schutz FA
    J Clin Oncol; 2011 Feb; 29(6):632-8. PubMed ID: 21205755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Hapani S; Wu S
    JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
    Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
    Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
    Schutz FA; Je Y; Choueiri TK
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
    Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
    Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
    Yang K; Wang YJ; Chen XR; Chen HN
    Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
    Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
    JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
    Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
    Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
    J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
    Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
    Hapani S; Sher A; Chu D; Wu S
    Oncology; 2010; 79(1-2):27-38. PubMed ID: 21051914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
    Hurwitz HI; Saltz LB; Van Cutsem E; Cassidy J; Wiedemann J; Sirzén F; Lyman GH; Rohr UP
    J Clin Oncol; 2011 May; 29(13):1757-64. PubMed ID: 21422411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis.
    Wang ZP; Zhang HF; Zhang F; Hu BL; Wei HT; Guo YY
    Eur J Clin Pharmacol; 2015 May; 71(5):517-24. PubMed ID: 25845654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.